The newly issued shares bring the company's total equity structure to 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. Because Class A shares carry ten votes each compared to the single vote per Class B share, the total voting power within the company now stands at 218,344,649. BioArctic disclosed these figures in compliance with the Swedish Financial Instruments Trading Act, which mandates regular reporting of changes in share capital and voting rights. The company, known for its work in neurodegenerative disease research and the development of Leqembi, maintains its listing on the Nasdaq Stockholm Large Cap exchange.
BioArctic expands share capital through August stock option exercise
Stockholm-based biopharmaceutical firm BioArctic AB increased its total share count to 88,744,685 by the end of August, following the issuance of 20,200 new Class B shares. The expansion stems from the exercise of stock options tied to the company's 2019/2028 incentive program for its employees.
Comments (0)
No comments yet. Be the first!